CXCL9

CXCL9 (MIG) is an interferon-γ-inducible CXC chemokine that orchestrates immune cell trafficking, angiostasis, and tissue remodeling through CXCR3-dependent and CXCR3-independent mechanisms. It signals through CXCR3 on activated T cells and NK cells to elicit calcium flux and chemotaxis — requiring the receptor's carboxyl-terminal domain, DRY motif, and β-arrestin1 for internalization — and is the principal macrophage-derived chemokine that recruits CXCR3⁺ CD8⁺ T cells into tumors, a function essential for the efficacy of immune checkpoint blockade (PMID:7595201, PMID:15150261, PMID:32640238, PMID:31636098). DPP-4 cleaves the two N-terminal residues of CXCL9 converting it from a CXCR3 agonist into a competitive antagonist, while CXCL9 also exerts angiostatic activity by directly binding and sequestering VEGF downstream of mTORC1/STAT1-driven transcription (PMID:40238455, PMID:27966526). Beyond immune recruitment, CXCL9 inhibits eosinophil function through CCR3/Rac2-dependent disruption of actin polymerization, directly induces Col1a1 in fibroblasts to promote dermal fibrosis via CXCR3, and opposes vascular smooth-muscle collagen deposition in pulmonary hypertension, illustrating context-dependent pro- and anti-fibrotic roles (PMID:15802529, PMID:36708947, PMID:35763380).

1. 1995 High

   Establishing that CXCL9 is a T-cell-selective chemoattractant resolved the cellular target specificity of this IFN-γ-inducible chemokine and showed that its C-terminal basic tail modulates bioactivity.

   Evidence Recombinant CXCL9 calcium flux and Boyden chamber chemotaxis on TILs and PBLs; C-terminal truncation analysis

   PMID:7595201

   Open questions at the time

   • Receptor identity unknown at this stage
   • In vivo relevance of C-terminal processing not tested
   • Mechanism of T-cell selectivity undefined
2. 1997 High

   Identifying CXCR3 as the shared receptor for CXCL9, CXCL10, and CXCL11 unified these IFN-γ-inducible chemokines into a single signaling axis and linked them to antiangiogenic and antitumor activity.

   Evidence Reciprocal desensitization assays on activated T cells; neovascularization and hematopoietic progenitor inhibition assays

   PMID:9060447

   Open questions at the time

   • Ligand-specific signaling bias through CXCR3 not resolved
   • Structural basis of receptor recognition unknown
3. 1998 Medium

   Demonstrating that neutralizing CXCL9 reduced IL-12-mediated tumor regression in vivo established its non-redundant role as an angiostatic effector in antitumor immunity.

   Evidence In vivo anti-CXCL9 neutralizing antibody in athymic mouse tumor models

   PMID:9738666

   Open questions at the time

   • Cannot distinguish T-cell-independent angiostatic from immune-mediated antitumor effects in this system
   • Contribution of CXCL10 not fully separated
4. 2002 High

   Showing that macrophages are the predominant CXCL9 source and that CXCL9 neutralization blocks CD4⁺ T cell recruitment defined the macrophage–CXCL9–T cell axis in transplant vasculopathy.

   Evidence Anti-CXCL9 antibody in MHC II-mismatched murine cardiac allograft model; MOMA-2 immunohistochemistry for cell source

   PMID:12368204

   Open questions at the time

   • Relative contribution of CXCL10/11 not fully controlled
   • Downstream intracellular signaling in recruited T cells not addressed
5. 2004 High

   Mapping the CXCR3 domains required for CXCL9-driven internalization, chemotaxis, and calcium mobilization revealed that CXCL9 signals preferentially through the receptor's C-terminal tail and β-arrestin1, distinct from CXCL11.

   Evidence CXCR3 deletion/point mutant constructs with internalization, chemotaxis, and calcium flux readouts

   PMID:15150261

   Open questions at the time

   • Biased signaling consequences (G-protein vs. β-arrestin) not measured for downstream gene expression
   • No structural data for ligand–receptor interface
6. 2005 High

   Discovering that CXCL9 inhibits eosinophil responses through CCR3 and Rac2 revealed a CXCR3-independent anti-inflammatory mechanism acting on allergic effector cells.

   Evidence CCR3⁻/⁻ and Rac2⁻/⁻ eosinophils; F-actin, Rac-GTP, and chemotaxis assays

   PMID:15802529

   Open questions at the time

   • Binding mode of CXCL9 to CCR3 not structurally defined
   • In vivo relevance in allergic disease not tested
7. 2007 Medium

   Finding that CXCL9 has direct antimicrobial activity against Streptococcus pyogenes expanded its function beyond chemotaxis to innate host defense, while identifying SIC as a bacterial counter-strategy.

   Evidence In vitro bactericidal assay; siRNA knockdown in pharyngeal epithelial cells

   PMID:17262710

   Open questions at the time

   • Antimicrobial mechanism (membrane disruption vs. other) not defined
   • In vivo contribution to pharyngeal defense not quantified
8. 2016 High

   Demonstrating that CXCL9 directly binds VEGF to block its receptor engagement, and that mTORC1/STAT1 drives CXCL9 transcription, defined a transcriptional–angiostatic circuit operating in osteoblasts.

   Evidence CXCL9–VEGF binding assay, STAT1 ChIP on CXCL9 promoter, mTORC1 inhibition, in vivo bone models

   PMID:27966526

   Open questions at the time

   • Stoichiometry and affinity of CXCL9–VEGF interaction not quantified biophysically
   • Relative contribution of CXCR3-mediated vs. VEGF-sequestration-mediated angiostasis not separated in vivo
9. 2019 High

   Multiple groups converged on tumor-associated macrophages as the critical CXCL9 source required for CXCR3-dependent CD8⁺ T cell infiltration and anti-PD-1/PD-L1 efficacy, establishing CXCL9 as a gatekeeper of checkpoint immunotherapy response.

   Evidence Macrophage depletion, CXCR3/CXCL9 genetic or antibody blockade in murine tumor models; patient scRNA-seq validation

   PMID:31636098 PMID:32640238

   Open questions at the time

   • Signals that sustain macrophage CXCL9 production in the tumor microenvironment beyond IFN-γ not fully mapped
   • Whether CXCL9 vs. CXCL10 have non-redundant roles in human ICB response not resolved
10. 2022 High

    Identifying opposing fibrotic roles — CXCL9 inhibits collagen deposition in pulmonary vascular smooth muscle yet promotes dermal fibrosis via fibroblast Col1a1 induction — revealed that CXCR3-mediated fibrotic outcomes are tissue- and cell-type-specific.

    Evidence hPASMC collagen assay with CXCR3 blockade (pulmonary); Cxcl9⁻/⁻ and Cxcr3⁻/⁻ mice in bleomycin skin fibrosis model with direct fibroblast stimulation (dermal)

    PMID:35763380 PMID:36708947

    Open questions at the time

    • Downstream transcription factors linking CXCR3 to Col1a1 induction in fibroblasts not identified
    • Whether DPP-4 cleavage modulates fibrotic vs. antifibrotic activity not tested
11. 2025 High

    Defining DPP-4 as a post-translational switch that converts full-length CXCL9 from a CXCR3 agonist to a competitive antagonist explained how proteolytic processing negatively regulates the CXCL9–CXCR3 axis and opened a strategy for engineering cleavage-resistant variants.

    Evidence Biochemical DPP-4 cleavage assay, CXCR3 activation assay, N-terminal glutamine mutant engineering

    PMID:40238455

    Open questions at the time

    • In vivo impact of DPP-4-processed CXCL9 on T cell recruitment and tumor immunity not demonstrated
    • Whether DPP-4-cleaved CXCL9 retains VEGF-binding or antimicrobial activities unknown

• Key unresolved questions include the structural basis of CXCL9–CXCR3 vs. CXCL9–CCR3 binding selectivity, the intracellular signaling cascade linking CXCR3 to opposing fibrotic outcomes in different cell types, and whether DPP-4-mediated antagonist conversion operates in vivo to shape tumor immune evasion.
• No crystal/cryo-EM structure of CXCL9 bound to CXCR3 or CCR3
• Signaling divergence downstream of CXCR3 in fibroblasts vs. smooth muscle cells undefined
• In vivo functional relevance of DPP-4-cleaved CXCL9 antagonism not tested